Indaptus Therapeutics (NASDAQ:INDP) Issues Earnings Results, Beats Estimates By $1.55 EPS

Indaptus Therapeutics (NASDAQ:INDP) posted its quarterly earnings data on Thursday. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($1.57) by $1.55, Zacks reports.

Indaptus Therapeutics Stock Performance

NASDAQ INDP traded up $0.04 on Thursday, reaching $1.06. The stock had a trading volume of 92,854 shares, compared to its average volume of 111,264. Indaptus Therapeutics has a 1 year low of $0.92 and a 1 year high of $8.57. The business has a 50 day moving average price of $2.64 and a 200 day moving average price of $2.23.

Hedge Funds Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 7.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on INDP shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Friday, July 17th. Wall Street Zen upgraded Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Indaptus Therapeutics has a consensus rating of “Sell”.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.